Central to PhoreMost’s mission is the development of a network of co-invested collaborators, who together will be far better placed than single organisations to tackle the complexity of developing future personalised medicines.
Phylogica Limited (ASX: PYC) is a biotechnology company based in Perth, Australia with a world-class drug discovery platform harnessing the rich biodiversity of nature to develop novel peptide therapeutics. The Company specialises in the discovery and delivery of biologics drugs against high value intracellular targets involved in cancer. The Company’s drug discovery platform is based on its proprietary Phylomer® libraries containing over 400 billion unique natural peptides, which have been optimised by evolutionary selection to have stable drug-like structures and to bind protein interfaces. Phylogica offers fully integrated drug discovery services to the pharmaceutical industry utilising its Phylomer® libraries and proprietary screening technologies. Its Pharma partners have included Genentech (a member of the Roche Group), MedImmune (the worldwide biologics arm of AstraZeneca), Pfizer, Cubist Janssen. PhoreMost is using Phylogica's Phylomer library as a core element in its SITESEEKER phenotypic screening platform.
Sentinel Oncology is an expert drug discovery company, using cutting edge structure based drug design methods to generate candidate drugs ready for clinical development. Founded in 2005 in Cambridge, UK, Sentinel Oncology is developing a portfolio of new cancer therapies and is committed to improving the treatment options for patients for whom there is currently an unmet medical need by combining their extensive pharmaceutical industry experience with a highly capital efficient business model. Sentinel Oncology is a fully integrated drug discovery company seeking to deliver high quality drug candidates from scientific concepts before partnering with the pharmaceutical and biotechnology industries. Sentinel is a key founding partner of PhoreMost Ltd, whose role is to perform precision medicinal chemistry on novel targets in PhoreMost's portfolio.
Cambridge University is a foundational partner in PhoreMost, providing the core intellectual property behind the ‘SITESEEKER®’ process (the Protein-interference platform) and its lead programme targeting KRAS mutant cancer types. Cambridge University, through Cambridge Enterprise, its technology transfer arm, has a long history of spinning out innovative research into the commercial arena and is dedicated to translating academic research into advancements in human health and society.
Avacta Group plc (AIM: AVCT) is the developer of Affimer® technology, a novel engineered alternative to antibodies, that has wide application in Life Sciences for diagnostics, therapeutics and as reagents for general research and development. Affimer technology has been designed to address many of the negative performance issues of antibodies, principally; the time taken to generate new antibodies, the reliance on an animal’s immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small 10 kDa protein scaffold that can be generated quickly to bind with high specificity and affinity to a wide range of biological and chemical targets. Avacta recently initiated an in-house pre-clinical Affimer therapeutic development programme with a focus on immuno-oncology and bleeding disorders and has several partnered development programmes including a major research partnership with Moderna Therapeutics. Avacta is also commercialising Affimer technology as reagents for research and diagnostics through custom Affimer services to provide bespoke solutions to customers and via a small on-line catalogue. PhoreMost is using Avacta's Affimer library as a core element in its SITESEEKER phenotypic screening platform.
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the country, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. PhoreMost and the Wistar are collaborating on a multi-project research partnership that combines Wistar’s knowledge and propriety biological systems with PhoreMost’s drug discovery expertise and unique screening capabilities. The shared goal is the identification and validation of novel druggable sites in disease pathways, and the development of a pipeline of novel therapeutic targets in the oncology and immunology space.